Half-Year 2022 Financial and Clinical Trials Update
HY 2022: Oncology portfolio rejuvenation on-going
YoY CER growth
Phesgo (+241%)
HER2 franchise
HER2 franchise
Herceptin
Perjeta (+5%)
+6%
•
Kadcyla (+14%) with growth ex-US due to adjuvant BC
Kadcyla (+14%)
·
Perjeta (+5%) driven by International
Tecentriq
+11%
Polivy (+91%)
Hematology
Rituxan
franchise
-7%
Gazyva (+8%)
Avastin
-29%
Alecensa
+19%
Cotellic +
Cotellic (+4%)
-3%
Zelboraf
Rozlytrek
+54%
Tarceva -32%
Gavreto n/a
CHFbn 0.0
1.0
2.0
3.0
4.0
5.0
Roche
•
Phesgo (CHF 325m): Conversion and geographic expansion ongoing
Tecentriq
Growth (+11%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC
Hematology franchise
•
Venclexta*: Growth driven by 1L AML and 1L & R/R CLL
•
Gazyva (+8%): Growth due to 1L FL and in 1L CLL
•
Polivy (+91%): Growth acceleration in the US due to R/R DLBCL;
•
EU approval in 1L DLBCL (POLARIX) achieved
⚫ Lunsumio: EU approval in 3L+FL achieved
Alecensa
Strong growth (+19%) driven by all regions
CER=Constant Exchange Rates; HY 2022 Oncology sales: CHF 10.1bn; CER growth -1%; * Venclexta sales booked by AbbVie and therefore not included; Polivy in collaboration with Seagen; BC=breast cancer; HCC-hepatocellular
carcinoma; SCLC=small cell lung cancer; NSCLC=non-small cell lung cancer; AML-acute myeloid leukemia; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL-diffuse large B cell lymphoma
21View entire presentation